Dr. Harvey Herschman's laboratory discovered the COX-2 gene, the target of the anti-inflammatory drugs Celebrex and Vioxx. Elevated COX-2 is a hallmark of many cancers such as colon, lung and breast. He and his colleagues are interested in the role of COX-2 in the initiation and progression of cancers. To study these areas, they are developing mouse models in which COX-2 can be conditionally over-expressed or suppressed in specific target tissues.
Herschman and associates also are interested in monitoring the development of tumors and in monitoring the delivery of gene therapy vectors to treat cancer. They have developed non-invasive imaging techniques to repeatedly and quantitatively monitor the location, magnitude and duration of gene expression from gene therapy vectors. These techniques can also be used to monitor the proliferation and location of immune cells infused into tumor-bearing animals.
Selected Cancer-Related Publications:
Gil JS, Machado HB, Herschman HR. A method to rapidly and accurately compare the relative efficacies of non-invasive imaging reporter genes in a mouse model and its application to luciferase reporters. Mol Imaging Biol. 2012 Aug;14(4):462-71.
Ishikawa TO, Oshima M, Herschman HR. Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis. 2011 Mar;32(3):417-26. Epub 2010 Dec 14
Ishikawa TO, Kumar IP, Machado HB, Wong KP, Kusewitt D, Huang SC, Fischer SM, Herschman HR. Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis. Mol Oncol. 2010 Apr;4(2):119-25. Epub 2010 Feb 2
Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2847-52. Epub 2009 Feb 5
Li HJ, Everts M, Yamamoto M, Curiel DT, Herschman HR. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Res. 2009 Jan 15;69(2):554-64.